Abstract:Thalidomide is effective for treating severe cutaneous lupus patients. The aim of this study was to observe the optimum effective and maintenance doses of thalidomide to maximize clinical benefit and minimize side effects for patients with cutaneous lupus in China. Sixty-nine patients with lupus rash from eight hospitals in China were enrolled and treated with different doses of thalidomide. We started the dose of thalidomide at 25 mg daily and gradually increased administration dose once a week until erythema was markedly improved. The effective and maintenance doses were documented. The size of skin lesions was noted once a week. Systemic lupus erythematosus disease activity index (SLEDAI) score, levels of erythrocyte sedimentation rate (ESR), and serum TNF-α were measured before and after treatment. The remission rates were evaluated weekly until 8 weeks. Sixty-eight percent of patients showed an effective dose of 50 mg daily; another 13, 10, and 9 % of patients had an effective dose of 100, 75, and 25 mg daily, respectively. The maintenance dose was 50 mg daily for 71 % of the patients, and 100, 75, and 25 mg daily for 9, 14, and 6 % of the patients. SLEDAI score and serum ESR levels significantly decreased 4 weeks after thalidomide treatment. At the end of the fourth week, the rates of complete remission, partial remission, and no response were 56 % ( n = 39), 41 % ( n = 28), and 3 % ( n = 2). At the eighth week, the rate of total remission rose up to 100 %. The most common side effects were drowsiness and constipation. No peripheral neuropathy was observed in these patients. Thalidomide at a dose of 50 mg daily may offer a better benefit to risk ratio in the treatment of Chinese cutaneous lupus patients.

Pharmaceutical care on the patient with severe drug eruption after application of le- nalidomide

Pharmaceutical Care for Patient with Bronchiectasia and Drug Induced Liver Injury by Clinical PharmacistsΔ

Exploration of Pharmaceutical Practice for Drug-induced Liver Injury

Pharmaceutical care for a patient with relapsed and refractory multiple myeloma

Nursing care of patients with severe drug eruption

Pharmaceutical Care of One Case with Pulmonary Infection and Impaired Immune Function

Pharmaceutical care performed by clinical pharmacists for one case of acute lymphocytic leukemia patient with infections

Pharmacists' role in multidisciplinary diagnosis and treatment in adverse reactions: A case report of interferon alfa-2b induced severe lupus

Pharmaceutical Practice of Clinical Pharmacist Involved in the Treatment of High-dose Methotrexate Intoxication

Analysis of 112 Cases of Severe Drug Eruption

Pharmaceutical Care for 1 Case of Severe Adverse Drug Reactions of Endometrial Carcinoma Patients Induced by Large Dose of Etoposide

Thalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China

Pharmaceutical care of a patient with delayed drug hypersensitivity reaction induced by multiple drugs

Pharmaceutical Practice for a Patient with 5-Fluorouracil Chemotherapy-induced Diarrhea and Neutropenia Associated with Fever

Pharmaceutical care for a child with severe juvenile dermatomyositis

Integrated pharmaceutical care for a case of severe adverse drug reactions induced by carbamazepine

Pharmaceutical Care for a Patient with SCLC Postchemotherapy

Clinical analysis on 33 patients with severe drug eruption caused by antiepileptic drugs

Pharmaceutical Care in Adverse Reactions of Gefitinib and Gemcitabine in Treating Lung Cancer

Pharmaceutical Practice of Clinical Pharmacist Participating in the Treatment of 2 Cases of Repeated Use of L-asparaginase Induced Pediatric Asthma

The clinical analysis of 73 cases with severe drug eruption